| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785529 | Bulletin du Cancer | 2018 | 9 Pages |
Abstract
Expression of Tim-3 and/or PD-1 on TILs impairs their function and correlates negatively with disease-free survival in HBV-HCC. Direct blockade of Tim-3 and PD-1 restores anti-tumor effects of TILs, which suggests a potential target for novel immunotherapy in HBV-HCC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Furong Liu, Gucheng Zeng, Shaotang Zhou, Xiaoshun He, Nianfeng Sun, Xiaofeng Zhu, Anbin Hu,